Skip to main content

Table 3 Summary of our analysis

From: Metformin plus lifestyle interventions versus lifestyle interventions alone for the delay or prevention of type 2 diabetes in individuals with prediabetes: a meta-analysis of randomized controlled trials

Outcome

Analysis or subgroup

Number of pooled RCTs

Estimate

95% CI

P value

Heterogeneity P value

Estimate after omitting Zhang et al.

Glycemic control

T2DM

at endpoints

5

0.85

[0.75, 0.97]

0.01

0.7

1 [0.75, 1.34]

FPG

at 3 months

4

-0.13

[-0.42, 0.15]

0.37

0.76

-

at 6 months

4

-0.07

[-0.31, 0.17]

0.58

0.75

-

at 12 months

3

-0.34

[-0.59, -0.08]

0.01

0.37

-

at endpoints

9

-0.12

[-0.33, 0.09]

0.26

0.04*

-0.21 [-0.39, -0.02]

HbA1c

at 3 months

2

-0.37

[-0.68, -0.05]

0.02

0.97

-

at 6 months

3

-0.35

[-0.62, -0.07]

0.01

0.7

-

at 12 months

2

-0.2

[-0.49, 0.09]

0.17

0.86

-

at endpoints

5

-0.1

[-0.19, -0.01]

0.03

0.89

-0.21 [-0.44, 0.02]

Plasma lipids

Triglycerides

at 6 months

3

-0.12

[-0.45, 0.20]

0.46

0.3

-

at 12 months

3

0.05

[-0.21, 0.30]

0.71

0.46

-

Overall

6

-0.02

[-0.22, 0.17]

0.8

0.45

-

Total cholesterol

at 6 months

3

0.1

[-0.20, 0.40]

0.52

0.49

-

at 12 months

3

-0.02

[-0.28, 0.23]

0.85

0.57

-

Overall

6

0.03

[-0.17, 0.22]

0.79

0.71

-

Serum HDL

at 6 months

3

0.03

[-0.27, 0.33]

0. 83

0.8

-

at 12 months

3

-0.02

[-0.28, 0.23]

0.87

0.95

-

Overall

6

0

[-0.19, 0.19]

0.99

0.99

-

Serum LDL

at 6 months

3

0.3

[0.00, 0.59]

0.05

0.58

-

at 12 months

3

-0.02

[-0.27, 0.24]

0.89

0.75

-

Overall

6

0.11

[-0.08, 0.31]

0.25

0.53

-

Body weight

Weight

at endpoints

4

0.12

[-0.03, 0.27]

0.11

0.07

0.22 [0.10, 0.33]

BMI

at 6 months

3

-0.12

[-0.42, 0.19]

0.45

0.41

-

at 12 months

3

0.04

[-0.22, 0.30]

0.76

0.71

-

at endpoints

7

-0.02

[-0.10, 0.07]

0.67

0.8

-0.03 [-0.22, 0.17]

WC

at endpoints

3

0

[-0.09, 0.10]

0.93

0.57

0.12 [-0.29, 0.53]

Blood pressure

SBP

at endpoints

5

-0.04

[-0.13, 0.05]

0.34

0.75

-0.16 [-0.41, 0.08]

DBP

at endpoints

4

0.04

[-0.05, 0.13]

0.42

0.95

-0.04 [-0.32, 0.24]

Insulin resistance

HOMA-IR

at endpoints

3

-0.06

[-0.16, 0.03]

0.17

0.86

-0.15 [-0.51, 0.22]

  1. T2DM, type 2 diabetes mellitus; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; CI, confidence interval. * Heterogeneity best resolved by omitting Zhang et al.
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us